People who take popular drugs for weight loss, such as Ozempic or Wegovy, may be at an increased risk of severe stomach problems, research published Thursday in the Journal of the American Medical Association finds
Historically, treatment rates for obesity have been alarmingly low, with less than 1% of obese individuals ever receiving anti-obesity medication or surgery
Generally, the data need to be interpreted with care due to compatibility issues in combining gt1b structural proteins with a gt2a replicase 24,25
The researchers noted that larger clinical trials are needed to better understand the role of GLP-1 receptor agonists in alcohol-related conditions
The Healthcare Institute is only considering these medications for people with the highest disease burden, it said on Thursday
The structure that supports it determines what the experience feels like